{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:59:23Z","timestamp":1790265563978,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:00:00Z","timestamp":1505865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00280-017-3431-5","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T02:34:12Z","timestamp":1505874852000},"page":"945-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment"],"prefix":"10.1007","volume":"80","author":[{"given":"Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra A.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Chacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-0816","authenticated-orcid":false,"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"key":"3431_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal JA (2015) Global cancer statistics, 2012. CA: A Cancer J Clin 65:87\u2013108. doi:\n                        10.3322\/caac.21262","journal-title":"CA: A Cancer J Clin"},{"issue":"9399","key":"3431_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399):1907\u20131917. doi:\n                        10.1016\/S0140-6736(03)14964-1","journal-title":"Lancet"},{"issue":"4","key":"3431_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390. doi:\n                        10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"1","key":"3431_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. doi:\n                        10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"32","key":"3431_CR5","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Kang YK, Lin DY et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31(32):4067\u20134075. doi:\n                        10.1200\/JCO.2012.45.8372","journal-title":"J Clin Oncol"},{"issue":"28","key":"3431_CR6","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson PJ, Qin S, Park JW et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31(28):3517\u20133524. doi:\n                        10.1200\/JCO.2012.48.4410","journal-title":"J Clin Oncol"},{"issue":"2","key":"3431_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","volume":"33","author":"C Cainap","year":"2015","unstructured":"Cainap C, Qin S, Huang WT et al (2015) Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33(2):172\u2013179. doi:\n                        10.1200\/JCO.2013.54.3298","journal-title":"J Clin Oncol"},{"issue":"6","key":"3431_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Rosmorduc O, Evans TR et al (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(6):559\u2013566. doi:\n                        10.1200\/JCO.2013.53.7746","journal-title":"J Clin Oncol"},{"issue":"4S","key":"3431_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/jco.2016.34.4_suppl.192","volume":"34","author":"GK Abou-Alfa","year":"2016","unstructured":"Abou-Alfa GK, Niedzwieski D, Knox JJ et al (2016) Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol 34(4S):192\u2013192","journal-title":"J Clin Oncol"},{"key":"3431_CR10","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet JM, Decaens T, Raoul JL et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509\u20133516. doi:\n                        10.1200\/JCO.2012.47.3009","journal-title":"J Clin Oncol"},{"key":"3431_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Kudo M, Assenat E et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312:57\u201367. doi:\n                        10.1001\/jama.2014.7189","journal-title":"JAMA"},{"key":"3431_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","volume":"16","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomized, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859\u2013870. doi:\n                        10.1016\/S1470-2045(15)00050-9","journal-title":"Lancet Oncol"},{"issue":"10064","key":"3431_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 389(10064):56\u201366. doi:\n                        10.1016\/S0140-6736(16)32453-9","journal-title":"The Lancet"},{"issue":"1","key":"3431_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer;129(1):245\u2013255. doi:\n                        10.1002\/ijc.25864","journal-title":"Int J Cancer"},{"issue":"1","key":"3431_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52\u201360. doi:\n                        10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"issue":"16","key":"3431_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","volume":"49","author":"J Bruix","year":"2013","unstructured":"Bruix J, Tak WY, Gasbarrini A et al (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49(16):3412\u20133419. doi:\n                        10.1016\/j.ejca.2013.05.028","journal-title":"Eur J Cancer"},{"key":"3431_CR17","unstructured":"Drug safety labeling changes. US food and drug administration website. \n                        https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203085s007lbl.pdf\n                        \n                    . Accessed on 23 May 2017"},{"issue":"3","key":"3431_CR18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11523-014-0352-7","volume":"10","author":"S Tabchi","year":"2015","unstructured":"Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10(3):445\u2013447","journal-title":"Target Oncol"},{"issue":"4","key":"3431_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1526924816664083","volume":"26","author":"N Angelis de\u2019","year":"2016","unstructured":"de\u2019 Angelis N, Landi F, Nencioni M et al (2016) Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant 26(4):348\u2013355. doi:\n                        10.1177\/1526924816664083","journal-title":"Prog Transplant"},{"issue":"11","key":"3431_CR20","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1432-2277.2012.01540.x","volume":"25","author":"K Staufer","year":"2012","unstructured":"Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M (2012) High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int 25(11):1158\u20131164. doi:\n                        10.1111\/j.1432-2277.2012.01540.x","journal-title":"Transpl Int"},{"issue":"4","key":"3431_CR21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1023\/A:1006990925122","volume":"19","author":"TA Ketter","year":"1999","unstructured":"Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM (1999) Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 19(4):511\u2013514","journal-title":"Cell Mol Neurobiol"},{"issue":"4S","key":"3431_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2017.35.4_suppl.344","volume":"35","author":"RS Finn","year":"2017","unstructured":"Finn RS (2017) Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial. J Clin Oncol 35(4S):344\u2013344. doi:\n                        10.1200\/JCO.2017.35.4_suppl.344","journal-title":"J Clin Oncol"},{"issue":"4","key":"3431_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","volume":"31","author":"VR Belum","year":"2013","unstructured":"Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 31(4):1078\u20131086. doi:\n                        10.1007\/s10637-013-9977-0","journal-title":"Invest New Drugs"},{"key":"3431_CR24","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1200\/jco.2013.31.15_suppl.3637","volume":"31","author":"A Grothey","year":"2013","unstructured":"Grothey A, Sobrero AF, Siena S et al (2013) Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. J Clin Oncol 31:3637\u20133637. doi:\n                        10.1200\/jco.2013.31.15_suppl.3637","journal-title":"J Clin Oncol"},{"issue":"9","key":"3431_CR25","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18(9):2658\u20132667. doi:\n                        10.1158\/1078-0432.CCR-11-1900","journal-title":"Clin Cancer Res"},{"issue":"4S","key":"3431_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1200\/JCO.2017.35.4_suppl.700","volume":"35","author":"M Ducreux","year":"2017","unstructured":"Ducreux M, \u00d6hler L, Scheithauer W et al (2017) Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: an interim analysis (IA) from the prospective, observational CORRELATE study. J Clin Oncol 35(4S):700\u2013700. doi:\n                        10.1200\/JCO.2017.35.4_suppl.700","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3431-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T05:31:38Z","timestamp":1510032698000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3431-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,20]]}}}